Photo via The Independent

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%

Read the original at The Independent ↗
Cite

Steenhuysen, J., & Erman, M. (2026, October 22). mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%. The Independent. https://www.independent.co.uk/news/world/americas/mrna-cancer-vaccine-moderna-merck-b3071828.html

Dated from the outlet's own feed. Check the original for its byline.

The Independent · collected 2026-10-22 · by Julie Steenhuysen, Michael Erman

Quick Summary

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to file for US regulatory approval, aiming to launch this personalized vaccine by 2027.
Written by AI on 2026-10-22, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-21, grounded in this article and the 7 other(s) covering the same event.

How they differ

8 outlets covered “mRNA Cancer Vaccine Breakthrough For Melanoma”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

The IndependentThis outlet22 Oct

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% (this article)
Toronto Star22 Oct

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning →
Time23 Oct

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% →
Daily Mail23 Oct

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist →
ABC News (AU)23 Oct

Researchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…

Australia at the heart of 'transformational' cancer vaccine breakthrough →
BBC23 Oct

A new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…

First personalised cancer vaccine cuts risk of disease returning in major trial →
Show 2 more outlets
Evening Standard23 Oct

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% →
CBC23 Oct

Moderna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study →

Where they agree and split

Framing

How the first headlines put it

Stated as fact7
The headlines (7)

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% The Independent · stated as fact

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Toronto Star · stated as fact

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% Time · stated as fact

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist Daily Mail · stated as fact

Australia at the heart of 'transformational' cancer vaccine breakthrough ABC News (Australia) · stated as fact

First personalised cancer vaccine cuts risk of disease returning in major trial BBC · stated as fact

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% Evening Standard · stated as fact

The full story: what happened, how it changed, and all 8 articles →

Compared with similar articles

This article reads unscored and hedges 0% of its claims. Each row says how that neighbour differs.
Toronto Star
Hedges 3 of 35 claims Outlet record 64/100
CBC News
Hedges 3 of 46 claims Outlet record 72/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
Daily Mail
Hedges 1 of 10 claims Outlet record 69/100
Evening Standard
Hedges 1 of 25 claims Outlet record 64/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 67/100
BBC News
Hedges 2 of 28 claims Outlet record 65/100

Story

mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
16
sentences that state something as happening or true
Uncertain
0%
0 of 16 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
59/100
The Independent's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-22 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Independent · 4757 article(s) · 10 correction(s) detected
Running correction rate · 10 correction(s)

Who wrote this

Julie Steenhuysen
1 article(s) here · 1 carrying a prediction
"There appears to be a sell-on-the-news reaction playing out here," William Blair analyst Myles Minter wrote in a research note, pointing out that Moderna shares remained up 525% this year even with Thursday's downward move.
The only article under this byline in the corpus.
Michael Erman
1 article(s) here · 1 carrying a prediction
"There appears to be a sell-on-the-news reaction playing out here," William Blair analyst Myles Minter wrote in a research note, pointing out that Moderna shares remained up 525% this year even with Thursday's downward move.
The only article under this byline in the corpus.

Topics

Independent Independent Membership Keytruda Merck Moderna

Subjects

Moderna ORG · 4× Merck ORG · 3× Bancel PERSON · 2× European Society for Medical Oncology ORG · 1× Hussein Tawbi PERSON · 1× Independent ORG · 1× Independent Membership ORG · 1× Madrid GPE · 1× Stephane Bancel PERSON · 1× the University of Texas MD Anderson Cancer Center ORG · 1×

Narrative

A large clinical trial combining Moderna's mRNA cancer vaccine with Merck's immunotherapy reduced the risk of melanoma death or recurrence by 42%, the companies announced on Thursday, potentially opening a new era in personalized oncology. Moderna shares closed more than 17% lower on Thursday after the trial findings leaked on an oncology website, despite having nearly quadrupled through Wednesday's close since August when the trial's success was first announced without full data. Merck stock also fell about 1.8%.
framing: assertive · carried by 1 article(s) · first seen 2026-10-22
"There appears to be a sell-on-the-news reaction playing out here," William Blair analyst Myles Minter wrote in a research note, pointing out that Moderna shares remained up 525% this year even with Thursday's downward move.
2026-10-22 · The Independent
mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% · assertive framing

Claims (16 extracted, 0 hedged)

A large clinical trial combining Moderna's mRNA cancer vaccine with Merck's immunotherapy reduced the risk of melanoma death or recurrence by 42%, the companies announced on Thursday, potentially opening a new era in personalized oncology. Moderna shares closed more than 17% lower on Thursday after the trial findings leaked on an oncology website, despite having nearly quadrupled through Wednesday's close since August when the trial's success was first announced without full data. Merck stock also fell about 1.8%. asserted
stock → combine → data
The Phase 3 trial, which tracked more than 1,100 patients, also revealed that the combination treatment reduced the risk of the cancer spreading by 38%. asserted
treatment → track → %
The findings mark the first data demonstrating that pairing a custom vaccine based on a patient's unique tumor mutations with a drug that boosts the immune system can successfully halt the disease. asserted
that → mark → disease
The vaccine was tested alongside Merck's Keytruda, one of the world's top-selling medicines. asserted
vaccine → test → medicines
Keytruda functions by removing a natural brake that cancer cells rely on to hide from immune attack. asserted
cells → function → attack
Meanwhile, the vaccine instructs patient cells to produce copies of specific mutations, allowing the immune system to seek out and destroy them. asserted
system → instruct → them
Moderna CEO Stephane Bancel stated that the findings herald a new chapter in treating cancer. asserted
findings → state → cancer
"With this ability to create new T cells that are specific to your tumor... the clinical impact is very profound, and as we saw in the Phase 2 (trial), very lasting," Bancel said in an interview. asserted
Bancel → create → interview
The companies are preparing to file for US regulatory approval, expecting to launch the personalized cancer vaccine in 2027, Bancel noted. asserted
Bancel → prepare → 2027
The results, evaluating patient outcomes over the initial two years following treatment, are scheduled for presentation on Saturday at the European Society for Medical Oncology conference in Madrid. asserted
results → evaluate → Madrid
Among subjects who received the vaccine paired with Keytruda, 82.2% remained cancer-free after two years, compared to 70% of those who received Keytruda alone. asserted
who → receive → Keytruda
It is not by chance," said Dr. Hussein Tawbi, a melanoma expert and trial investigator at the University of Texas MD Anderson Cancer Center. asserted
Tawbi → say → Center
Ahead of the meeting, several Wall Street analysts noted that investors were looking for the combination to cut the risk of recurrence by 40% or more. asserted
combination → note → %
"There appears to be a sell-on-the-news reaction playing out here," William Blair analyst Myles Minter wrote in a research note, pointing out that Moderna shares remained up 525% this year even with Thursday's downward move. asserted
shares → appear → move
Minter added that the findings were "great data, in our view, but investors will continue to debate the fundamental valuation. asserted
investors → add → valuation
" The trial assessed nine doses of the vaccine, known as intismeran, administered with Keytruda beginning 13 weeks after surgery to remove melanoma lesions, comparing responses against the standard single-therapy treatment of Keytruda alone. asserted
trial → assess → Keytruda
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support